Amarin's Vascepa Associated With Stroke Reduction

Loading...
Loading...

Amarin Corporation plc AMRN has announced new prespecified and post hoc analyses from the REDUCE-IT study, evaluating Vascepa (icosapent ethyl). Data were presented at International Stroke Conference 2021.

  • The REDUCE-IT STROKE analyses examined stroke rates across the enrolled patient population (n=8179).
  • The study showed 28% and 32% significant reductions in first and total strokes, demonstrated with Vascepa compared to placebo.
  • Reductions in first and total ischemic strokes each by 36%, without increasing hemorrhagic stroke, in statin-treated patients with elevated cardiovascular risk.
  • Consistent reductions in overall stroke and ischemic stroke were observed across multiple subgroups.
  • Price Action: AMRN shares are trading 3.4% higher at $6.70 in market trading hours on the last check Wednesday.
Posted In: BiotechNewsHealth CareFDAGeneralStroke
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...